Medical Necessity of Unclassified Drugs for Left Ankle Pain/Haglund's Deformity

Understanding the Case and Treatment

The surgical procedures performed, including bursa excision, Achilles tendon repair, and partial calcanectomy, are appropriate standard treatments for Haglund's deformity that has not responded to conservative management 1

For patients with Type 2 Diabetes undergoing surgical procedures, careful medication management is essential due to increased risks of complications 2
The American College of Cardiology notes that morbid obesity is a significant risk factor for both diabetes and osteoarthritis and may complicate surgical recovery 3

Without specific information about which medication C9399 represents, it is impossible to determine medical necessity, according to the Diabetes/Metabolism Research and Reviews 1
If C9399 represents a specialized medication for diabetes management, this would need to be clearly documented with appropriate indications, as suggested by medical guidelines 4
The Annals of the Rheumatic Diseases indicate that if C9399 represents a pain management medication, its necessity would depend on the specific drug and whether it falls outside standard perioperative pain protocols 5

Medical necessity for C9399 cannot be established without identification of the specific medication this code represents, and additional documentation should be requested, including specific identification of the medication and clinical rationale for its use 1, 2, 6

For patients with Type 2 Diabetes undergoing surgical procedures, careful medication management is essential due to increased risks of complications, according to the American Diabetes Association 7, 8
When choosing medications for overweight or obese patients with Type 2 Diabetes, their effect on weight should be considered, and medications associated with weight gain should be minimized when possible, as recommended by the American Diabetes Association 7
Patients with diabetes who undergo foot surgery may require special perioperative management due to their higher risk of complications, as noted by the Infectious Diseases Society of America and the European Society of Cardiology 9, 10

The medication represented by C9399 must be specifically identified to determine its appropriateness for a patient with Type 2 Diabetes and morbid obesity, with consideration of its effect on weight and potential for complications, according to the American Diabetes Association and the American Gastroenterological Association 7, 8, 11
Documentation of how the medication addresses the patient's specific needs related to her multiple comorbidities is necessary, as emphasized by the American Diabetes Association 7, 8